CORRECTION article

Front. Cardiovasc. Med., 27 October 2022

Sec. Cardio-Oncology

Volume 9 - 2022 | https://doi.org/10.3389/fcvm.2022.1070597

Corrigendum: Research on the mechanism and prevention of hypertension caused by apatinib through the RhoA/ROCK signaling pathway in a mouse model of gastric cancer

  • Department of Hypertension Center, Lanzhou University Second Hospital, Lanzhou, China

In the published article, there was an error in the author list. Author Qingjian He was erroneously included and should have been thanked in the Acknowledgements statement instead. The corrected author list and Acknowledgements appear below.

Wenjuan Wang, Caie Li, Chenchen Zhuang, Haodong Zhang, Qiongying Wang, Xin Fan, Miaomiao Qi, Runmin Sun and Jing Yu*

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Acknowledgments

We are grateful for the extremely careful and thoughtful reviews of the editor and reviewers, which greatly improved this manuscript. We also thank all members of the Cuiying Biomedical Research Center of Lanzhou University Second Hospital and Qingjian He of Zhoushan Hospital of Zhejiang Province.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Summary

Keywords

hypertension, apatinib, gastric cancer, RhoA/ROCK signaling pathway, Y27632

Citation

Wang W, Li C, Zhuang C, Zhang H, Wang Q, Fan X, Qi M, Sun R and Yu J (2022) Corrigendum: Research on the mechanism and prevention of hypertension caused by apatinib through the RhoA/ROCK signaling pathway in a mouse model of gastric cancer. Front. Cardiovasc. Med. 9:1070597. doi: 10.3389/fcvm.2022.1070597

Received

15 October 2022

Accepted

17 October 2022

Published

27 October 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

9 - 2022

Updates

Copyright

*Correspondence: Jing Yu

This article was submitted to Cardio-Oncology, a section of the journal Frontiers in Cardiovascular Medicine

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics